Fig. 1: Baseline to posttreatment changes in biomarkers of AD and related dementias biomarkers in plasma and cerebrospinal.
From: Rapamycin treatment for Alzheimer’s disease and related dementias: a pilot phase 1 clinical trial
Baseline and post-treatment plasma (a–e) and cerebrospinal fluid (f–j) (N = 10 participants) biomarker changes were evaluated using paired samples t-tests or Wilcoxon signed rank tests. FDR-corrected p-values and color coding by participant are displayed. Mean difference from baseline to post-treatment (a) pTau-181: −0.22 pg/ml; (b) Aβ40: −8.56 pg/ml; c Aβ42: −0.668 pg/ml; (d) GFAP: −27.70 pg/ml; (e) NfL: 0.84 pg/ml; (f) pTau-181: 2.64 pg/ml; (g) Aβ40: 615.57 pg/ml; (h) Aβ42: 21.51 pg/ml; (i) GFAP: 6,262.21 pg/ml; and (j) NfL: 367.19 pg/ml. ADRD Alzheimer’s disease and related dementias, p-tau phosphorylated tau, Aβ amyloid beta, GFAP glial fibrillary acidic protein, NfL neurofilament light.
